



TTS 2024

ISTANBUL TURKEY
September 22-25
30th International Congress of The Transplantation Society

Organized in partnership with



Endorsed by



The Clinical Pharmacist Interventions in Solid Organ Transplant Recipients

www.tts2024.org

**Aysel Pehlivanlı^{1,2}, Fatma İrem Yeşiler³, Tuğba Yanık Yalçın⁴, Helin Şahintürk³,
Bilgen Başgut^{1,2}, Pınar Zeyneloğlu³, Mehmet Haberal⁵**

¹ *Başkent University, Faculty of Pharmacy, Department of Pharmacology*



² *Başkent University, Ankara Hospital, Clinical Pharmacy and Drug Information Center*

³ *Başkent University, Faculty of Medicine, Department of Anesthesiology and Critical Care*

⁴ *Başkent University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology*

⁵ *Başkent University, Faculty of Medicine, Department of General Surgery, Division of Transplantation*

Introduction



The United Network for Organ Sharing (UNOS) requires that all transplant programs identify at least one pharmacist to be responsible for providing pharmaceutical care to SOT recipients



This study aims  to evaluate **drug-related problems (DRPs)** by **a clinical pharmacy service** with a **multidisciplinary approach** in SOT recipients

- lifelong immunosuppression
- multiple drug use (polypharmacy)
- drug-related problems (DRPs)


Material and Methods



Retrospective descriptive study
December 7, 2022 - February 20, 2023
in the **Intensive Care Unit (ICU)**





DRPs were categorized according to the
Pharmaceutical Care Network Europe (PCNE) V9.1 classification



Primary outcomes:
the **interventions proposed** and the **rate of acceptance** by the SOT team

Findings

39 patients were included in determining DRPs



27 liver (71.1%), 10 kidney (26.3%), and 2 heart (5.3%) transplant recipients

15 DRPs were found in 13 (34.2%) patients

- **“Treatment safety” (53.3 %)** was the most common problem of DRPs
- **“Dose selection” (53.3 %), and “Inappropriate combination of drugs, or drugs and herbal medications, or drugs and dietary supplements” (33.3 %)** were the most common causes
- The most common medication class in DRPs was **antimicrobial drugs (93.3 %)**

The SOT team accepted 86.74 % of the interventions

Conclusion

- DRPs are **common** among SOT recipients
- DRP prevalence and acceptance rates of clinical pharmacist recommendations are **similar to the previous studies**
- **Clinical pharmacy services in the multidisciplinary approach** may improve the therapeutic outcomes of SOT recipients



References

1. Yang H, Li L, Hu X, et al. Impact of pharmacist-led post-transplant medication management for kidney transplant recipients: A retrospective pre-and post-intervention study. J Clin Pharm Ther. 2019 Aug;44(4):603-610.
2. Wiegel JJ, Olyaei AJ. The role of the pharmacist in the management of kidney transplant recipients. Indian J Urol. 2016;32:192-198.



TTS 2024 ISTANBUL TURKEY
September 22-25
30th International Congress of The Transplantation Society



The
Transplantation
Society

Organized in Partnership with



Endorsed by

